This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celldex Therapeutics Shares Fall on Breast Cancer Study Changes

11/05/14 - 04:26 PM EST

Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk

READ FULL POST

Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership

11/04/14 - 01:40 PM EST

Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.

READ FULL POST

FDA Review of Rockwell's Dialysis Therapy Raises Doubts About Need

11/04/14 - 10:22 AM EST

Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.

READ FULL POST

Aegerion Board Expresses Support for Embattled CEO Amid Drug Use Accusations

10/29/14 - 09:16 AM EDT

Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board's support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex.

READ FULL POST

Arena Skimps on Data Disclosure From Weight-Loss Combo Study

10/29/14 - 07:30 AM EDT

Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.

READ FULL POST

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

10/27/14 - 11:02 AM EDT

FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.

READ FULL POST

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

10/22/14 - 11:52 AM EDT

But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.

READ FULL POST

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

10/22/14 - 08:39 AM EDT

My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.

READ FULL POST

Some Potential Targets for Shire to Buy With $1.6B in Free Money

10/21/14 - 09:29 AM EDT

Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?

READ FULL POST

First Detailed Look at Celgene Crohn's Disease Pill Impresses

10/20/14 - 10:56 AM EDT

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs